Myriad Genetics (MYGN) Fundamental Analysis: Revenue, Earnings & Valuation

6.03 / 10

Outperform

Fundamental rating is Outperform with a 6.0/10 quality score. Profit‑MV and Cash‑MV are positive, supporting earnings strength, while Asset‑MV is slightly negative. Revenue‑MV is robust, but gross profit margin receives a low score. Overall, the balance sheet and cash flow are adequate, though margin efficiency lags.

Analysis Checks(9/10)

Revenue-MV

Value0.87

Score3/3

Weight25.62%

1M Return9.51%

Inventory turnover ratio

Value8.53

Score2/3

Weight-0.95%

1M Return-0.56%

Gross profit margin (%)

Value69.93

Score0/3

Weight-7.50%

1M Return-5.42%

Profit-MV

Value0.68

Score2/3

Weight14.72%

1M Return6.36%

Income tax / Total profit (%)

Value7.39

Score3/3

Weight5.18%

1M Return2.26%

Current assets turnover ratio

Value2.62

Score3/3

Weight18.57%

1M Return7.57%

Fixed assets turnover ratio

Value4.91

Score2/3

Weight0.02%

1M Return0.01%

Cost of sales ratio (%)

Value30.07

Score2/3

Weight-6.03%

1M Return-3.62%

Asset-MV

Value-0.55

Score2/3

Weight35.96%

1M Return13.10%

Cash-MV

Value-0.66

Score2/3

Weight14.42%

1M Return6.19%

Is MYGN undervalued or overvalued?

MYGN scores 6.03/10 on fundamentals and holds a Discounted valuation at present. Backed by its -68.45% ROE, -44.38% net margin, -1.20 P/E ratio, 1.19 P/B ratio, and -180.14% earnings growth, these metrics solidify its Outperform investment rating.